BeOne Medicines Q3 2025: total revenue up 41% to $1.4B, GAAP EPS $1.09

BeOne Medicines Ltd.

2025-Q3 EPS reported $0.15 revenue$3,844,863,000

Total revenue $1.41B, +41% YoY; BRUKINSA revenue $1.0B, +51% YoY.
GAAP diluted EPS $1.09; non-GAAP diluted EPS $2.65, up from $0.48 a year ago.
GAAP net income $124.8M vs loss $121.4M in Q3 2024; adjusted net income $303.7M.
47 abstracts accepted at ASH 2025; pipeline advances with sonrotoclax (BCL2 inhibitor) and BTK CDAC BGB-16673.
Free cash flow $354.5M, up 548% from $54.7M in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.